Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recilisib sodium
- Development stage
- Unknown
- Lead developer
- Onconova Therapeutics
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Ex-RAD (recilisib sodium) is an experimental small-molecule radioprotectant being developed by Onconova Therapeutics in collaboration with the U.S. Department of Defense. It is designed to protect cells from the lethal effects of ionizing radiation, specifically for the treatment of Acute Radiation Syndrome (ARS). Unlike many other radioprotective agents that function as free-radical scavengers, Ex-RAD acts as a kinase inhibitor that modulates intracellular signaling, damage sensing, and DNA repair pathways. Clinical development has included Phase I studies in healthy volunteers to assess safety and tolerability following subcutaneous administration.
- Brand names
- Ex-RAD
- Other names
- recilisib4-carboxystyryl-4-chlorobenzylsulfone sodium
02
Targets
PI3K (Phosphoinositide-3-kinase regulatory subunit 6)
Beyond the preview
Go deeper on recilisib sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recilisib sodium.